Evaluation of the effect of a porcine reproductive and respiratory syndrome (PRRS) modified-live virus vaccine on sow reproductive performance in endemic PRRS farms
Introduction
Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically important swine infectious diseases affecting the swine industry worldwide. The causative agent is PRRS virus (PRRSV) which belongs to the order Nidovirales, family Arteriviridae, and genus Arterivirus. Antigenic and genetic analyses have established two major PRRSV genotypes, type 1 PRRSV (European genotype) and type 2 PRRSV (North American genotype), which share approximately 60% nucleotide identity genome-wide (Allende et al., 1999, Snijder et al., 2013, Dea et al., 1996, Murtaugh et al., 1995, Nelsen et al., 1999). Infection with PRRSV is associated with reproductive failure in sows and respiratory distress in growing pigs (Zimmerman et al., 2012).
PRRSV infection can be epidemic and endemic. Epidemic infection occurs when immunologically naïve hosts are infected regardless of the individual’s age. Endemic infection occurs in susceptible subpopulations that have either declining or no immunity. To date, PRRS remains endemic in most Korean swine farms despite wide use of commercial vaccines against it. Instead of eradication, PRRSV control may be a more efficient and realistic strategy based on the common use of continuous production systems with high pig densities and high PRRSV prevalence. One of the most common control strategies for endemic PRRSV in Korean farms is vaccination. In the field, in PRRSV-positive pig farms, 89% of sows typically receive a PRRS vaccine (http://www.kahpa.or.kr).
A commercially available PRRS modified-live virus (MLV) vaccine (Fostera™PRRS, Zoetis, Parsippany, NJ, USA), based on a virulent US PRRSV isolate (P129 strain, type 2 PRRSV) and attenuated using CD163-expressing cell lines, was licensed for protection against respiratory diseases in 2012 and reproductive failure in 2015. Vaccination with this PRRS MLV vaccine led to improved growth performance and decreased mortality in growing pigs when evaluated under field conditions (Park et al., 2014a). However, no field studies evaluating the efficacy in reproductive performance of vaccinated sows have been performed to date. The objective of this field study was to evaluate the effect of this vaccine on the reproductive performance of sows from endemic farms.
Section snippets
Farm history
The clinical field trial was conducted on 3 pig farms with a history of endemic PRRSV infection. Farm A is a 230-sow farrow-to-finish farm with all-in/all-out in the farrowing and nursery rooms, and continuous flow in growing and finishing rooms. Six months after the initial outbreak, the reproductive performance and mortality in suckling pigs returned almost back to the levels before the PRRS outbreak; nevertheless abortion (abortion rate 2.3–4.7%) has recurred sporadically in pregnant sows
Reproductive performance
Sows in VacB and VacC groups had a significantly (P < 0.05) longer gestation length compared to sows in UnVacB and UnVacC groups. Sows in VacC group had significantly (P < 0.05) higher numbers of live-born piglets compared to sows in UnVacC group. Sows in VacA, VacB, and VacC groups had significantly (P < 0.05) lower number of stillborn piglets at birth compared to sows in UnVacA, UnVacB, and UnVacC groups. No significant difference was observed in the number of mummified fetuses between vaccinated
Discussion
The current study provides strong evidence that this PRRS MLV vaccine confers heterologous protection to sows in endemic PRRS farms. Comparison of the ORF5 nucleotide sequence between the isolated field viruses (lineage 5 from two farms and lineage 1 from one farm) and the vaccine virus (lineage 8) show a sequence identity between 86.5 and 91%. This means that the field circulating viruses from all the farms are considered quiet genetically distinct from the vaccine virus, suggesting that the
Competing interests
None.
Acknowledgements
The author’s research was supported by contract research funds (Grant no. 550-20160024) of the Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine and by the BK 21 Plus Program (Grant no. 5260-20150100) for Creative Veterinary Science Research.
References (26)
- et al.
Sow performance in an endemically porcine reproducive and respiratory syndrome (PRRS)-infected farm after sow vaccination with an attenuated PRRS vaccine
Vet. Microbiol.
(2005) - et al.
Cross reactivity of immune responses to porcine reproductive and respiratory syndrome virus infection
Vaccine
(2017) - et al.
Use of ELISPOT and ELISA to evaluate IFN-gamma: IL-10 and IL-4 responses in conventional pigs
Vet. Immunol. Immunopathol.
(2005) - et al.
Comparison of the virulence of European and North American genotypes of porcine reproductive and respiratory syndrome virus in experimentally infected pigs
Vet. J.
(2013) - et al.
Gradual development of the interferon-gamma response of swine to porcine reproductive and respiratory syndrome virus infection or vaccination
Virology
(2003) - et al.
Passive transfer of virus-specific antibodies confers protection against reproductive failure induced by a virulent strain of porcine reproductive and respiratory syndrome virus and establishes sterilizing immunity
Virology
(2002) - et al.
Evaluation of the efficacy of a new modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS) against heterologous PRRSV challenge
Vet. Microbiol.
(2014) - et al.
Similarity of European porcine reproductive and respiratory syndrome virus strains to vaccine strain is not necessarily predictive of the degree of protective immunity conferred
Vet. J.
(2008) - et al.
Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge
Vet. Microbiol.
(2007) - et al.
North American and European porcine reproductive and respiratory syndrome viruses differ in non-structural protein coding regions
J. Gen. Virol.
(1999)
Antigenic variability among North American and European strains of porcine reproductive and respiratory syndrome virus as defined by monoclonal antibodies to the matrix protein
J. Clin. Microbiol.
Comparison of the antigen distribution of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus
Vet. Pathol.
Terminology for classifying swine herds by porcine reproductive and respiratory syndrome virus status
J. Swine Health Prod.
Cited by (14)
Cross-protection of a modified-live porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine against a heterologous PRRSV-1 challenge in late-term pregnancy gilts
2018, Veterinary MicrobiologyCitation Excerpt :A PRRSV-2 MLV vaccine (Fostera™ PRRS, Zoetis, Parsippany, NJ, USA) was licensed in 2017 in most Asian countries for use in gilts and sows to protect against reproductive failure caused by PRRSV-2. In a previous study, this PRRSV-2 based MLV vaccine was able to improve the reproductive performance of sows in farms with endemic PRRSV-2 infection under field conditions (Jeong et al., 2017). However, no controlled study has been carried out yet to evaluate the cross-protection of this PRRSV-2 MLV vaccine against PRRSV-1.
Congenital tremor and splay leg in piglets – insights into the virome, local cytokine response, and histology
2022, BMC Veterinary Research
- 1
Both authors contributed equally to this work.